Neoleukin Therapeutics Inc

NASDAQ:NLTX  
6.88
-0.13 (-1.85%)
Earnings Announcements

Neoleukin Therapeutics Announces Year End 2020 Financial Results

Published: 03/25/2021 20:11 GMT
Neoleukin Therapeutics Inc (NLTX) - Neoleukin Therapeutics Announces Year End 2020 Financial Results.
Neoleukin Therapeutics - Cash and Cash Equivalents of $192.6 Million Expected to Fund Operations Into 2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.28

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.30

More details on our Analysts Page.